After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Geron Corp. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Geron Corp. is $1.73B. A total of 22.97 million shares were traded on the day, compared to an average of 10.33M shares.
In the most recent transaction, O’Farrell Elizabeth G. bought 6,607 shares of GERN for 2.28 per share on Aug 24 ’23. After the transaction, the Director now owns 7,407 company shares. In a previous transaction on Aug 24 ’23, O’Farrell Elizabeth G. bought 6,579 shares at 2.28 per share. GERN shares that Director owns now total 26,220.
Among the insiders who sold shares, LAWLIS V BRYAN disposed of 35,000 shares on May 11 ’23 at a per-share price of $3.00. This resulted in the Director holding 0 shares of GERN after the transaction. In another insider transaction, Molineaux Susan sold 35,000 shares at $2.48 per share on May 01 ’23. Company shares held by the Director now total 0.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, GERN has a high of $3.73 and a low of $1.64.
As of this writing, GERN has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.1. The company reported an EPS of -$0.08 in the last quarter, which was 20.00% higher than expectations of -$0.1.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. GERN’s latest balance sheet shows that the firm has $183.72M in Cash & Short Term Investments as of fiscal 2021. There were $55.00M in debt and $45.52M in liabilities at the time. Its Book Value Per Share was $0.46, while its Total Shareholder’s Equity was $126.42M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GERN is Buy with a score of 4.80.
